Article Type
Changed
Fri, 01/04/2019 - 11:12
Display Headline
Multiple myeloma: newly approved drugs forge paradigm shift toward chronic disease

The pace of drug development for multiple myeloma was dizzying in 2015, with 5 regulatory approvals for the treatment of relapsed/refractory disease, 3 in a single month. As we stand on the brink of another paradigm shift in the management of this disease, we discuss the new classes of drugs and how they are shaping standard of care with the potential to make multiple myeloma a chronic disease.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Issue
The Journal of Community and Supportive Oncology - 14(4)
Publications
Topics
Page Number
180-186
Legacy Keywords
multiple myeloma, immunomodulatory drugs, IMiDs, thalidomide, lenalidomide, proteasome inhibitors, bortezomib, carflzomib, dexamethasone, ixazomib, histone deacetylase, HDAC, panobinostat, monoclonal antibodies, mAb, elotuzumab, SLAMF7, daratumumab, CD38, immunotherapy, programmed cell death-1, PD-1, nivolumab, atezolizumab, ipilimumab
Sections
Article PDF
Article PDF
Related Articles

The pace of drug development for multiple myeloma was dizzying in 2015, with 5 regulatory approvals for the treatment of relapsed/refractory disease, 3 in a single month. As we stand on the brink of another paradigm shift in the management of this disease, we discuss the new classes of drugs and how they are shaping standard of care with the potential to make multiple myeloma a chronic disease.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

The pace of drug development for multiple myeloma was dizzying in 2015, with 5 regulatory approvals for the treatment of relapsed/refractory disease, 3 in a single month. As we stand on the brink of another paradigm shift in the management of this disease, we discuss the new classes of drugs and how they are shaping standard of care with the potential to make multiple myeloma a chronic disease.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 14(4)
Issue
The Journal of Community and Supportive Oncology - 14(4)
Page Number
180-186
Page Number
180-186
Publications
Publications
Topics
Article Type
Display Headline
Multiple myeloma: newly approved drugs forge paradigm shift toward chronic disease
Display Headline
Multiple myeloma: newly approved drugs forge paradigm shift toward chronic disease
Legacy Keywords
multiple myeloma, immunomodulatory drugs, IMiDs, thalidomide, lenalidomide, proteasome inhibitors, bortezomib, carflzomib, dexamethasone, ixazomib, histone deacetylase, HDAC, panobinostat, monoclonal antibodies, mAb, elotuzumab, SLAMF7, daratumumab, CD38, immunotherapy, programmed cell death-1, PD-1, nivolumab, atezolizumab, ipilimumab
Legacy Keywords
multiple myeloma, immunomodulatory drugs, IMiDs, thalidomide, lenalidomide, proteasome inhibitors, bortezomib, carflzomib, dexamethasone, ixazomib, histone deacetylase, HDAC, panobinostat, monoclonal antibodies, mAb, elotuzumab, SLAMF7, daratumumab, CD38, immunotherapy, programmed cell death-1, PD-1, nivolumab, atezolizumab, ipilimumab
Sections
Citation Override
JCSO 2016;14(4):180-186
Disallow All Ads
Alternative CME
Article PDF Media